» Articles » PMID: 19297005

High Prevalence of Chronic Myocarditis in Dilated Cardiomyopathy Referred for Left Ventriculoplasty: Expression of Tenascin C As a Possible Marker for Inflammation

Overview
Journal Hum Pathol
Specialty Pathology
Date 2009 Mar 20
PMID 19297005
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The objectives of this study were to analyze the incidence of chronic myocarditis in dilated cardiomyopathy and to evaluate the diagnostic value of tenascin C for assessing inflammatory activity in the resected myocardium. Dilated cardiomyopathy patients with chronic myocarditis have a poor clinical outcome despite recent advances in medical treatments. Therefore, a precise diagnosis of inflammatory activity is critical to ensuring appropriate therapy. Tenascin C is an extracellular matrix glycoprotein that plays an important role in tissue remodeling in various heart diseases. Myocardial samples obtained during left ventriculoplasty from 64 patients (50 +/- 13 years, 56 men and 8 women) with dilated cardiomyopathy were examined by immunostaining for tenascin C. Histologic diagnosis was based on the Dallas criteria modified by the International Society and Federation of Cardiology task force. Nine cases (14%) had active myocarditis, 21 (33%) had borderline myocarditis, and 34 (53%) had no myocarditis. Intense tenascin C expression was observed at the site of active inflammation, with abundant cell accumulation, and in organized granulation tissue during the resolving phase but not in scar tissue during the healing phase. The ratio of tenascin C-positive area to the whole myocardium in the active and borderline myocarditis groups was significantly greater than that in the noninflammatory group. These findings suggest a high prevalence of chronic myocarditis in dilated cardiomyopathy patients and that tenascin C may prove to be a useful marker for distinguishing inflammatory cardiomyopathy from other types of dilated cardiomyopathy.

Citing Articles

Targeting myocardial inflammation: investigating the therapeutic potential of atrial natriuretic peptide in atrial fibrosis.

Zhu N, Li T, Bai Y, Sun J, Guo J, Yuan H Mol Biol Rep. 2024; 51(1):506.

PMID: 38622341 PMC: 11018689. DOI: 10.1007/s11033-024-09393-w.


Extracellular matrix complexity in biomarker studies: a novel assay detecting total serum tenascin-C reveals different distribution to isoform-specific assays.

Ozanne J, Lewis M, Schwenzer A, Kurian D, Brady J, Pritchard D Front Immunol. 2023; 14:1275361.

PMID: 38077374 PMC: 10703424. DOI: 10.3389/fimmu.2023.1275361.


Tenascin-C predicts IVIG non-responsiveness and coronary artery lesions in kawasaki disease in a Chinese cohort.

Li Y, Xu Z, Wu L, Liang X, Zhao L, Liu F Front Pediatr. 2022; 10:979026.

PMID: 36582508 PMC: 9792982. DOI: 10.3389/fped.2022.979026.


Elevated Serum Tenascin-C Predicts Mortality in Critically Ill Patients With Multiple Organ Dysfunction.

Xu Y, Li N, Gao J, Shang D, Zhang M, Mao X Front Med (Lausanne). 2021; 8:759273.

PMID: 34901073 PMC: 8661593. DOI: 10.3389/fmed.2021.759273.


Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients.

Hajjo R, Sabbah D, Bardaweel S, Tropsha A Vaccines (Basel). 2021; 9(10).

PMID: 34696294 PMC: 8541143. DOI: 10.3390/vaccines9101186.